Led by Bartley P. Griffith, MD, Thomas E. and Alice Marie Hales Distinguished Professor in Transplant Surgery at the University of Maryland School of Medicine, the University of Maryland Medical Center was among the first in the country to implant a new resilient bovine pericardial valve with anti-calcification properties for early aortic valve replacement patients. The new tissue valve, inspiris resilia, advances the field of aortic valve replacement surgery by incorporating expansion technology for potential future valve-in-valve replacement while also preventing the need for anticoagulation therapy.
Current generation of tissue valves will last between 10 to 15 years but with this new valve model, patients can benefit from resilia tissue treatment with enhanced durability that can last beyond 15 years. The new valve also incorporates specialized pre-set technology designed to be opened wider should it wear out after 15 to 18 years. Replacement of inspiris resilia valves then, can be treated like a blocked valve using a catheter-based, valve-in-valve strategy. This prevents the future need for breast bone incisions and patients can benefit from shorter length of stay as well as no required rehabilitation.
Ranked as a high-performing hospital by U.S. News and World Report in aortic valve surgery, the University of Maryland Medical Center was pivotal in FDA-approval of the new resilia tissue valve model having enrolled the most patients in the U.S. during clinical study.
Learn more about the high-performing Aortic Valve Disease Program at the University of Maryland Heart and Vascular Center.
Call 410-328-5842 or visit umm.edu/referral to make a referral.